Because third-generation EGFR inhibitors such as osimertinib (AZD9291), rociletinib (CO-1686), and olmutinib (HM61713) show impressive efficacy, especially in T790M-positive patients with a response rate of approximately 50% and a median PFS ranging from 9.6 months to 13.1 months [90–92], a clinical trial targeting lung cancer harboring T790M as well as surveying the application of liquid biopsy for T790M was conducted. This evidence concerns the gene EGFR and lung carcinoma.